YLT192, a Novel, Orally Active Bioavailable Inhibitor of VEGFR2 Signaling with Potent Antiangiogenic Activity and Antitumor Efficacy in Preclinical ModelsYong Xia, Luoting Yu|Scientific Reports|2014Cited by 33